CLAIMS

1. Use of a photoactivated composition for the manufacture of a medicament for the treatment of an oral disease, wherein said composition comprises:

at least one oxidant,

at least one photoactivator which is a fluorescent compound; and

at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin,

in association with a pharmacologically acceptable carrier;

wherein the oral disease is chosen from gingivitis, ~~periodontal disease,~~ oral thrush, lichen planus, stomatitis, oral mucositis, oral submucous fibrosis, and glossitis.

~~2. Use of a photoactivated composition for the manufacture of a medicament for oral disinfection, wherein said composition comprises:~~

~~at least one oxidant;~~

~~at least one photoactivator which is a fluorescent compound; and~~

~~at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin;~~

~~in association with a pharmacologically acceptable carrier.~~

2. ~~3.~~ The use according to claim 1 ~~or 2~~, wherein the oxidant is selected ~~chosen~~ from hydrogen peroxide, carbamide peroxide and benzoyl peroxide.

3. ~~4.~~ The use according to claim 1 ~~or 2~~, wherein the oxidant is selected ~~chosen~~ from a peroxy acid and an alkali metal percarbonate.

4. ~~5.~~ The use according to any one of claims 1 to 3 4, wherein the composition further comprises at least one hydrophilic gelling agent.

5. ~~6.~~ The use according to claim 4 ~~5~~, wherein the hydrophilic gelling agent is selected ~~chosen~~ from glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, carbopol® polymers, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin, and gelatin.

6. ~~7.~~ The use according to any one of claims 1 to 5, wherein the photoactivator is selected ~~chosen~~ from a xanthene derivative dye, an azo dye, a biological stain, and a carotenoid.

7. ~~8.~~ The use according to claim 6 ~~7~~, wherein said xanthene derivative dye is selected ~~chosen~~ from a fluorene dye, a fluorone dye, and a rhodole dye.

8. ~~9.~~ The use according to claim 7 ~~8~~, wherein said fluorene dye is selected ~~chosen~~ from a pyronine dye and a rhodamine dye.

9. ~~10.~~ The use according to claim 8 ~~9~~, wherein said pyronine dye is selected ~~chosen~~ from pyronine Y and pyronine B.

10. ~~11.~~ The use according to claim 8 ~~9~~, wherein said rhodamine dye is selected ~~chosen~~ from rhodamine B, rhodamine G and rhodamine WT.

11. ~~12.~~ The use according to claim 7 ~~8~~, wherein said fluorone dye is selected ~~chosen~~ from fluorescein and fluorescein derivatives.

12. ~~13.~~ The use according to claim 11 ~~12~~, wherein said fluorescein derivative is selected ~~chosen~~ from phloxine B, rose bengal, and merbromine.

13. ~~14.~~ The use according to claim 11 ~~12~~, wherein said fluorescein derivative is selected ~~chosen~~ from eosin Y, eosin B and erythrosine B.

14. ~~15.~~ The use according to claim 13 ~~14~~, wherein said fluorescein derivative is Eosin Y.

15. ~~16.~~ The use according to claim 6 ~~7~~, wherein said azo dye is selected ~~chosen~~ from methyl violet, neutral red, para red, amaranth, carmoisine, allura red AC, tartrazine, orange G, ponceau 4R, methyl red, and murexide-ammonium purpurate.

16. ~~17.~~ The use according to claim 6 ~~7~~, wherein said biological stain is selected ~~chosen~~ from saffranin O, basic fuchsin, acid fuschin, 3,3' dihexylocarbocyanine iodide, carminic acid, and indocyanine green.

17. ~~18.~~ The use according to claim 6 ~~7~~, wherein said carotenoid is selected ~~chosen~~ from crocetin, a-crocin (S,S-diapo-S,S-carotenoic acid), zeaxanthine, lycopene, α-carotene, β-carotene, bixin, and fucoxanthine.

18. ~~19.~~ The use according to claim 6 ~~7~~, wherein said carotenoid is present in the composition as a mixture selected ~~chosen~~ from saffron red powder, annatto extract and brown algae extract.

19. ~~20.~~ The use according to any one of claims 1-18 ~~19~~, wherein said composition further comprises at least one chelating agent selected ~~chosen~~ from ethylenediaminetetraacetic acid (EDTA) and ethylene glycol tetraacetic acid (EGTA).

20. ~~21.~~ The use according to any one of claims 1-19 ~~20~~, wherein the composition further comprises a biofilm or a dental plaque disclosing agent.

21. ~~22.~~ The use according to any one of claims 1-20 ~~21~~, wherein the composition is adapted to be topically applied on a patient's oral mucosa and wherein exposure of said composition to actinic light causes activation of the fluorescent compound.

22. ~~23.~~ The use according to claim 21 ~~22~~, wherein exposure of the composition to actinic light for a period of less than about 5 minutes causes activation of said fluorescent compound.

23. ~~24.~~ The use according to claim 21 ~~22~~, wherein exposure of said composition to actinic light for a period of about 60 seconds to about 5 minutes causes activation of said fluorescent compound.

24. ~~25.~~ The use according to claim 21 ~~22~~, wherein exposure of said composition to actinic light for a period of less than about 5 minutes per cm^2 of an area to be treated causes activation of said fluorescent compound.

25. ~~26.~~ The use according to claim 21 ~~22~~, wherein exposure of said composition to actinic light for a period of about 60 seconds to about 5 minutes per cm^2 of an area to be treated causes activation of said fluorescent compound.

26. ~~27.~~ The use according to any one of claims 21-25 ~~22-26~~, wherein the source of actinic light is over an area to which said composition has been applied.

27. ~~28.~~ The use according to any one of claims 21-26 ~~22-27~~, wherein said oral mucosa is a gingiva or a portion thereof.

28. ~~29.~~ The use according to any one of claims 21-26 ~~22-27~~, wherein said oral mucosa is on or near at least one tooth.

29. ~~30.~~ The use according to any one of claims 21-26 ~~22-27~~, wherein said actinic light is visible light having a wavelength between about 400 nm and about 700 nm.

30. ~~31.~~ The use according to any one of claims 1 to 29 ~~30~~, wherein said composition is applied on a patient's oral mucosa prior to a supragingival debridement, a scaling/root planing, or both.

31. ~~32.~~ The use according to any one of claims 1 to 29 ~~30~~, wherein said composition is applied on a patient's oral mucosa after a supragingival debridement, a scaling/root planing, or both.